Cancer Bioenergetics
Course Information
Date: AnytimeDuration: 60 Minutes
Location: Virtual
Audience: ACVIM, ECEIM, ECVIM-CA and ECVN Diplomates and candidates
Specialty: Oncology
Type: On Demand
CE Hours: 1.0
Course Overview
One of the revised hallmarks of cancer is dysregulated energy metabolism. This session will cover the historical and modern concepts of glucose utilization and energy generation in cancer, how it may affect tumor cell behavior, and strategies for intervention.
Learning Objectives:
- Compare the historical and modern concepts in cancer of glucose utilization and energy generation.
- Discuss how glucose utilization and energy generation affects tumor cell behavior.
- Identify strategies for intervention in cancer bioenergetics.
RACE Application Status
This module has been submitted and approved for 1.0 hours of Anytime, Non-Interactive-distance medical continuing education credit in jurisdictions which recognize AAVSB RACE-approval.
For additional questions, please contact us at Learning@ACVIM.org.
Presenter
Douglass H. Thamm, VMD, DACVIM (Oncology)
Barbara Cox Anthony Professor of Oncology
Director of Clinical Research
Colorado State University Flint Animal Cancer Center
Dr. Thamm is the Barbara Cox Anthony Professor of Oncology and Director of Clinical Research at the Colorado State University Flint Animal Cancer Center. He is also a member of the Developmental Therapeutics Section of the University of Colorado Comprehensive Cancer Center and the Cell and Molecular Biology Graduate Program at Colorado State University.
Dr. Thamm received his Bachelor’s and VMD degrees from the University of Pennsylvania. He completed an Oncology Residency at the University of Wisconsin and was a researcher there for 5 additional years before joining the faculty at CSU in 2004. He has authored over 140 peer-reviewed publications and 20 book chapters in veterinary and basic cancer research, was Oncology Section Editor for the 2 most recent editions of Kirk’s Current Veterinary Therapy and is Co-Editor-In-Chief of the journal Veterinary and Comparative Oncology. His clinical and research interests include novel targeted therapies for animal and human cancer and ways to integrate these therapies with existing treatment.